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AbstrAct:
The mechanism of HTLV-1 transformation of cells to Adult T cell leukemia (ATL) 
remains not fully understood.  Currently, the viral Tax oncoprotein is known to be 
required to initiate transformation.  Emerging evidence suggests that Tax is not 
needed to maintain the transformed ATL phenotype.  Recent studies have shown 
that HTLV-1 transformed cells show deregulated expression of cellular microRNAs 
(miRNAs).  Here we discuss the possibility that early ATL cells are Tax-oncogene-
addicted while late ATL cells are oncogenic microRNA (oncomiR) – addicted.  The 
potential utility of interrupting oncomiR addiction as a cancer treatment is broached.  
HTLV-1 was the first human retrovirus to be isolated.   
It was identified in 1980 by Robert Gallo and co-workers   
[1]; that initial finding was followed closely by important 
contributions  from  Japanese  virologists  [2].    HTLV-1 
is causative of Adult T cell leukemia [3,4], a treatment 
refractory T cell cancer found endemically in Japan [5] 
and  elsewhere [6].  Studies on this virus over the past 
three decades have provided insight into oncogene- and 
oncogenic microRNA- (oncomiR) addiction in leukemic 
transformation.  
HTLV-1  encodes  a  viral  Tax  oncoprotein  [7-9] 
whose expression confers prosurvival and proproliferative 
properties to infected cells. Extant findings have shown 
that Tax is sufficient to transform human T cells [10,11]. 
Hence, the expression of Tax-alone in transgenic mice was 
found to be fully proficient for in vivo tumorigenesis [12-
14].  Indeed, current data are consistent with the notion 
that Tax expression in infected humans greatly accelerates 
the in vivo cycling of T cells [15]. Intriguingly, when ATL 
patients are followed over time, a puzzling finding reveals 
that Tax expression in vivo is absent from approximately 
60%  of  late  leukemias  [16]. Thus,  unlike  other  virus-
induced human malignancies such as the cervical cancers 
caused  by  human  papilloma  virus  (HPV),  in  which 
the  expression of the viral E6 and E7 oncoproteins are 
required for tumor maintenance [17], late ATL cells are 
apparently  not  addicted  to  the Tax  oncoprotein.   Why 
might ATL cells extinguish Tax expression? A possible 
reason is because this viral protein represents the major 
target  for  cytotoxic  T-lymphocytes  (CTL)  in  infected 
patients [18,19].  Accordingly, the loss of Tax expression 
in vivo would facilitate the escape of virus-infected cells 
from CTL surveillance; and this seemingly would benefit 
disease progression.  
A  currently  accepted  model  for  ATL  genesis  by 
HTLV-1 is that the viral Tax oncogene is used for the 
initiation,  but  not  the  maintenance,  of  leukemogenesis 
(Figure 1).  In this regard, the HTLV-1 – ATL transformation 
mechanism  appears  not  to  subscribe  to  the  oncogene 
addiction model of carcinogenesis [20].  What might then 
be some of the factor(s) needed for ATL cells to maintain 
their leukemic phenotype in the absence of Tax?  One 
possible explanation rests with the observation that all 
ATL cells exhibit virus-mediated attenuation of the cell’s 
spindle  assembly  checkpoint  [21]  and  are  thus  highly 
aneuploid [9].  Potentially, this selected presentation of 
aneuploid  chromosomes  could  be  sufficient  per se  for 
maintaining  the  transformed  ATL  phenotype  [22].    A 
second  possibility  is  that  transformed ATL  cells  have 
acquired altered expression of cellular microRNAs that 
are capable, in a Tax-independent fashion, of maintaining 
oncogenesis (e.g. oncomiRs [23] [24]).  
Altered miRNA expression has indeed been linked 
to carcinogenesis. Early on, it was found that the loss of Oncotarget 2010; 1:  453 - 456 454 www.impactjournals.com/oncotarget
miR-15a  and  miR-16-1  correlated  with  B-cell  chronic 
lymphocytic leukemia [25]. Later, miRNA signatures for 
various cancers were described and linked to oncogenic 
transformation  and  found  to  be  diagnostic  of  tumor 
types [23,26].  The deregulated expression of miRNAs 
in HTLV-1 transformed cells has also been reported in 
three independent publications [27-29].  In parsing the 
specific miRNA changes published in the three HTLV-1 
studies, there appears to be very little over lap amongst 
most of the miRNA moieties [30].  Nonetheless, there 
was an intriguing consensus amongst the three findings.   
For example, in the study by Yeung et al., the authors 
reported  that  the  tumor  suppressor  protein  TP53INP1 
in  HTLV-1-  infected/transformed  cells  was  targeted 
for repression by the upregulated expression of miR-93 
and miR-130b [27].  By comparison, in the subsequent 
study by Pichler et al., TP53INP1 was also reported to 
be targeted in HTLV-1 infected/transformed cells, but by 
the upregulated expression of miR-21, -24, -146a, and 
-155 [28].  Remarkably, separate from the in vitro HTLV-
1 infected/transformed cells, Bellon et al. and Yeung et 
al. further investigated in vivo ATL leukemic cells from 
patients; and both noted upregulated miR-155 expression 
[27,29] which would be consistent with a silencing of 
TP53INP1 by miR-155 [31].  Thus, collectively, the three 
studies agree and converge on TP53INP1 as one of the 
important miRNA-regulated targets in ATL transformation 
by HTLV-1.  
Based on the above data, one biological scenario 
is that late ATL cells may indeed be oncomiR-addicted 
while early ATL cells are Tax-oncogene-addicted (Figure 
1).   Recently, Watashi et al. have provided additional 
evidence that NIH 3T3 mouse cells can be transformed 
by singular over expression of either miR-93 or miR-130b 
[32].   They discovered two small molecule compounds 
that can be used to reduce the over expression of miR-
93 or miR-130b, and they showed that the treatment of 
miR-93- or miR-130b transformed NIH 3T3 cells using 
such  compounds  reversed  tumorigenesis  [32].    These 
results support the interpretation that in certain settings 
oncomiR-addicted tumors exist, and that this addiction 
could  represent  a  potential  treatment  target  for  such 
cancers.  
One  might  reason  that  a  logical  extension  is  to 
treat  cancers  by  reducing  oncomiR  expression  as  well 
as targeting oncogene expression.  Reality may be more 
complicated than this simple logic.   Some studies have 
shown that a generalized down regulation of miRNAs is 
frequently seen in human cancers [26,33].  While it is not 
fully understood how general miRNA down regulations 
could propitiate carcinogenesis, such observations do raise 
caution that small molecule inhibitors of oncomiR activity 
needs to be utilized judiciously and monitored carefully to 
ensure that they ameliorate rather than exacerbate cancers.     
Further investigations are needed to conclusively verify 
oncomiR inhibition as an important treatment option in 
cancers.
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figure 1.  Potential stages of oncogene-addiction and oncomir-addiction in HtlV-1 transformation of Atl leukemic t cells.  Virus-
infected cells either initiate transformation after Tax expression or enter apoptosis/senescence.  At this stage the cells could be regarded as 
Tax-oncogene-addicted.  Subsequently, the expression of Tax in ATL cells is extinguished, and maintenance of the transformed phenotype in 
the cells is postulated to emerge from altered miRNA expression (oncomiR-addiction).  Inhibition of the activity of oncomiRs can send such 
cells in tissue culture into apoptosis/senescence.  (The figure is modified from Jeang, KT, JFMA, 2010, in press).  Oncotarget 2010; 1:  453 - 456 455 www.impactjournals.com/oncotarget
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